In Brief: Medtronic
This article was originally published in The Gray Sheet
Medtronic: Firm's Vitatron subsidiary receives FDA go-ahead to market its Vitatron Legacy II DR, D, SR and S pacemakers. The DR pacemaker features "automatic mode switching and a wide range of flexibility and automaticity for efficient and effective dual chamber, rate responsive pacing therapy," Medtronic says. The line offers "significantly more service life than earlier Vitatron models and...a new, easier-to-implant shape," Medtronic says...
You may also be interested in...
Public Company Edition: Lixte’s small uplisting was the only biopharma initial public offering in the US during Thanksgiving week, but IPOs are ramping up again. Also, LifeSci launched its second SPAC and in follow-on offerings Reata brought in $281m and Intellia grossed $175m.
Orladeyo is the first oral prophylactic approved in the US for hereditary angioedema, with Japan and EU approvals expected to follow. Pricing of $485,000 a year undercuts segment leader.
Results of Study to Assess Statin Residual Risk with Epanova in High Cardiovascular Risk Patients with Hypertriglyceridemia “should prompt reconsideration of [OTC] mixed omega-3 fatty acid products for [atherosclerotic cardiovascular disease] prevention,” say cardiologists in an editorial published with JAMA study.